Title :

Neo-Adjuvant Use of Sorafenib for Hepatocellular Carcinoma Awaiting Liver Transplantation

Author(s) :

Minoux, Kate [Auteur]
Lassailly, Guillaume [Auteur]
Hôpital Claude Huriez [Lille]
Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille]
Ningarhari, Massih [Auteur]
Lubret, Henri [Auteur]
El Amrani, Medhi [Auteur]
Canva, Valérie [Auteur]
Hôpital Claude Huriez [Lille]
Truant, Stéphanie [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille]
Mathurin, Philippe [Auteur]
Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille]
Louvet, Alexandre [Auteur]
Hôpital Claude Huriez [Lille]
Lebuffe, Gilles [Auteur]
Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille]
Goria, Odile [Auteur]
Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau [ADEN]
Service d'Hépato-Gastroentérologie [CHU Rouen]
Nguyen-Khac, Eric [Auteur]
Groupe de Recherche sur l'alcool et les pharmacodépendances - UMR INSERM_S 1247 [GRAP]
CHU Amiens-Picardie
Boleslawski, Emmanuel [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Dharancy, Sebastien [Auteur]
Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille]

Journal title :

Transplant International

Publisher :

Wiley

Publication date :

2022-11-09

ISSN :

0934-0874

HAL domain(s) :

Sciences du Vivant [q-bio]/Médecine humaine et pathologie

English abstract : [en]

Data on efficacy and safety of sorafenib in a neoadjuvant setting for HCC awaiting liver transplantation (LT) are heterogeneous and scarce. We aimed to investigate the trajectory of patients treated with sorafenib while ...
Show more >Data on efficacy and safety of sorafenib in a neoadjuvant setting for HCC awaiting liver transplantation (LT) are heterogeneous and scarce. We aimed to investigate the trajectory of patients treated with sorafenib while awaiting LT. All patients listed for HCC and treated with sorafenib were included in a monocentric observational study. A clinical and biological evaluation was performed every month. Radiological tumor response evaluation was realized every 3 months on the waiting list and every 6 months after LT. Among 327 patients listed for HCC, 62 (19%) were treated with Sorafenib. Sorafenib was initiated for HCC progression after loco-regional therapy (LRT) in 50% of cases and for impossibility of LRT in 50% of cases. The mean duration of treatment was 6 months. Thirty six patients (58%) dropped-out for tumor progression and 26 (42%) patients were transplanted. The 5-year overall and recurrent-free survival after LT was 77% and 48% respectively. Patients treated for impossibility of LRT had acceptable 5-year intention-to-treat overall and post-LT survivals. Conversely, patients treated for HCC progression presented high dropout rate and low intention-to-treat survival. Our results suggest that it is very questionable in terms of utility that patients treated for HCC progression should even be kept listed once the tumor progression has been observed.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277

Source :

Harvested from HAL